Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

CYP = Cytochrome p-450

Primary Purpose: Other: This is a Phase 1 clinical pharmacology thorough QT study being
conducted as a post marketing requirement

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Healthy volunteers, ages 18 to 49 years old

- BMI 18 to 32 kg/m2

- Women must not be pregnant or breastfeeding

Exclusion Criteria:

- A personal history of clinically relevant cardiac disease, symptomatic or
asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors
for torsades de pointes (eg, heart failure)

- History of hypokalemia, personal history or family history of prolonged QT interval,
or family history of sudden cardiac death at a young age

- Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
administration: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, HR <45 bpm

- Second or third degree heart block prior to study drug

- Positive urine screen for drugs of abuse

- Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human
Immunodeficiency Virus (HIV)-1, -2 antibody

- Any of the following lab results outside of the ranges specified below prior to
dosing: Alanine aminotransferase (ALT) >upper limit of normal (ULN), aspartate
aminotransferase (AST) >ULN, Total bilirubin >ULN, Direct bilirubin >ULN, Creatinine
>ULN, Serum potassium
- History of allergy to Moxifloxacin, Efavirenz or related compounds